VivoSeq
Musculoskeletal

Osteonecrosis

21

Pipeline Programs↗

4

Active Trials↗

9

Companies Involved↗

Osteonecrosis is an emerging landscape with 21 programs across 9 companies. The most active players are Rohto Pharmaceutical Co., Ltd., Sclnow Biotechnology Co., Ltd., Pfizer. 3 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

48/100

Pipeline Velocity

11/100

Mech. Concentration

25/100

Completion Rate

50/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

R

Rohto Pharmaceutical Co., Ltd.

1 program

Phase 1S

Sclnow Biotechnology Co., Ltd.

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2B

Bone Therapeutics S.A

1 program

Phase 3Bayer logo

Bayer

1 program

Phase 3V

Validus Pharmaceuticals

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

85%

Small molecule

22 of 26 classified programs — the dominant modality here.

15%ALL OTHERSCell therapy415%

Small molecule leads; the ring shows all 26 classified programs, each share of the total. Modality classified for 100% of 32 pipeline programs.

Analysis

Trial Status

29

clinical trials

Unknown status9 · 31%
Completed8 · 28%
Terminated3 · 10%
Withdrawn3 · 10%
Suspended2 · 7%
Recruiting1 · 3%
Other3 · 10%

Clinical Trials

Trial Activity

29 trials

Human Amniotic Membrane (hAM) for Stage II Maxillomandibular Osteonecrosis Management
Recruiting·—·Phase 2·NCT05664815·66 enrolled
A Phase II Trial of RAB001 (LLP2A-Alendronate) for Steroid-Induced Early-Stage Osteonecrosis of the Femoral Head
Active, not recruiting·ZZhongShan LaiBo RuiChen BioMedicine Co.,Ltd.·Phase 2·NCT07471880·161 enrolled
Effect of Hyperbaric Oxygen Therapy on Osteonecrosis of the Femoral Head When Combined With 3D Navigated Core Decompression With Bone Marrow Aspirate Concentrate
Not yet recruiting·YYale University·Preclinical·NCT06931301·400 enrolled
Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ)
Enrolling by invitation·UUniversity of Washington·Phase 3·NCT03040778·100 enrolled
Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI
Completed·SStanford University·Phase 4·NCT02893293·14 enrolled
Use of Topical Phenytoin in Bisphosphonate-related Osteonecrosis of the Mandible
Completed·SShiraz University of Medical Sciences·N/A·NCT03269214·20 enrolled
Evaluate the Effect of Bone Marrow Derived Cd133+ Cells in Patient With Osteonecrosis of Femoral Head
Completed·RRoyan Institute·Phase 1·NCT01198080·10 enrolled
Autologous Osteoblastic Cells Implantation to Early Stage Osteonecrosis of the Femoral Head
Completed·EErasme University Hospital·Phase 2·NCT02890537·82 enrolled
Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head
Completed·VVericel Corporation·Phase 3·NCT00505219·11 enrolled
Impact of Topical Pentoxifylline and Tocopherol in Treatment and Prevention of Medically-related Osteonecrosis of the Jaws
Completed·UUniversity of Catania·N/A·NCT06409546·48 enrolled
Study Into the Effect of Ibandronate for the Treatment of Bone Marrow Edema in Relation to Spontaneous or Non-traumatic Osteonecrosis of the Knee: A Randomized Double-blind, Placebo-controlled Trial
Completed·UUniversity Hospital, Basel, Switzerland·Phase 3·NCT00532220·30 enrolled
Mesenchymal Stem Cells in Osteonecrosis of the Femoral Head
Completed·BBanc de Sang i Teixits·Phase 1/2·NCT01605383·23 enrolled
The Study of Early Stage Osteonecrosis of Femoral Head With Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ONFH)
Suspended·SSclnow Biotechnology Co., Ltd.·Phase 1/2·NCT03180463·30 enrolled
Infiltration of Medical Ozone for the Treatment of Medication-Related Osteonecrosis of the Jaws (MRONJ)
Suspended·UUniversity of Palermo·Phase 1/2·NCT05036837·50 enrolled
Use of Adipose Derived Regenerative Cells in Bilateral Femoral Head Osteonecrosis
Terminated·MMayo Clinic·Phase 1·NCT03269409·8 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)